Form 4: GeneDx COO Sells Shares for Tax Obligations

GeneDx Holdings Corp.'s Chief Operating Officer, Bryan Dechairo, sold a portion of his Class A Common Stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Bryan Dechairo, Chief Operating Officer of GeneDx Holdings Corp. (WGS), acquired 9,374 shares of Class A Common Stock on February 1, 2026, through the settlement of Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Class A Common Stock for no consideration upon settlement.
• On February 2, 2026, Mr. Dechairo sold a total of 3,413 shares of Class A Common Stock in multiple transactions at weighted average prices ranging from $96.7676 to $100.3146.
• The sales were explicitly undertaken to cover tax withholding obligations associated with the RSU vesting and were not discretionary transactions.
• Following these transactions, Mr. Dechairo beneficially owns 5,961 shares of Class A Common Stock directly and holds 28,123 additional RSUs that vest annually, with the first tranche having vested on February 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, it's a non-discretionary 'sell to cover' for tax purposes following RSU vesting, which is a standard compensation practice and indicates continued executive service.

Positives

• The vesting of 9,374 Restricted Stock Units (RSUs) indicates continued service of a key executive, Bryan Dechairo, to GeneDx Holdings Corp.
• The RSU vesting represents a non-cash compensation component for the COO, aligning his interests with shareholder value.
• The sales were non-discretionary, solely to cover tax withholding obligations, which is a standard practice for RSU settlements.

Negatives

• The sale of 3,413 shares by a Chief Operating Officer, even for tax purposes, represents a reduction in direct insider ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and expected occurrence in the biotechnology and genomics industry, particularly for executives receiving equity compensation like Restricted Stock Units. This type of transaction does not typically signal a change in an executive's long-term view of the company, unlike discretionary sales.

Related Party Transactions

• The acquisition of shares through RSU settlement and subsequent sale by the Chief Operating Officer constitutes a related party transaction, as it involves an executive of the company.

Stakeholder Impact

• Shareholders: The sale of shares by the COO, even for tax purposes, slightly reduces the percentage of shares held by other shareholders, though the amount is small relative to total outstanding shares. It also provides transparency into executive compensation practices.
• Employees: The RSU vesting and 'sell to cover' mechanism is a common form of executive compensation, which can be a positive for employee morale if seen as fair and standard practice.

Next Steps

• Remaining 28,123 RSUs will vest annually, subject to Bryan Dechairo's continued service to the Issuer on each vesting date.

Key Dates

Recommendation

The filing details a routine 'sell to cover' transaction by a key executive to satisfy tax obligations upon RSU vesting. This is a standard practice and not indicative of a discretionary sale based on a change in outlook. Therefore, it does not provide a basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

GeneDx Holdings Corp, WGS, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Executive Compensation, Bryan Dechairo, Chief Operating Officer